Atopic Dermatitis Disease
Adults, children maintain mild AD during treatment-free period follow Vtama cream 1%
ORLANDO — Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive treatment-free days, according to a presentation at the American Academy of Dermatology Annual Meeting.
Moderate-to-Severe Atopic Dermatitis: Optimizing Care Across Specialties
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Mastering Hand and Foot Atopic Dermatitis: From Immunology to Innovative Treatments
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Moderate-to-Severe Atopic Dermatitis: Separating Fact From Myth in Primary Care
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Getting Under the Skin: Updates in the Treatment of Pediatric Atopic Dermatitis
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Vtama cream results are ‘fully replicable’ in second of two phase 3 studies
The second of two phase 3 studies evaluating Vtama cream 1% in adults and children aged as young as 2 years with atopic dermatitis showed consistent safety and efficacy results, Dermavant Sciences announced in a press release.
Dupixent shows consistent, long-term efficacy in real-world studies
MIAMI BEACH, Florida — In two-real world studies, Dupixent treatment led to similar rapid and sustained improvements in patients with atopic dermatitis, according to a poster presentation at South Beach Symposium.
LiVDerm, Healio continue media partnership for 21st annual South Beach Symposium
Healio and LiVDerm are continuing their media partnership for the 21st annual South Beach Symposium taking place in Miami Beach from Feb. 9 to 12.
Q&A: Eczema Awareness Month highlights patient challenges, resources
The National Eczema Association has dedicated October to raising awareness of this inflammatory skin condition, with 2022 focused on the facts of the disease as well as the stories of those who live with it.
Atopic dermatitis disease burden multidimensional
Atopic dermatitis disease burden is affected by severity and time spent managing the disease, according to a study.